About voyager therapeutics inc - VYGR
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
VYGR At a Glance
Voyager Therapeutics, Inc.
75 Hayden Avenue
Lexington, Massachusetts 02421
| Phone | 1-857-259-5340 | Revenue | 80.00M | |
| Industry | Biotechnology | Net Income | -65,002,000.00 | |
| Sector | Health Technology | Employees | 172 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
VYGR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.087 |
| Price to Book Ratio | 1.035 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.324 |
| Enterprise Value to Sales | 1.30 |
| Total Debt to Enterprise Value | 0.42 |
VYGR Efficiency
| Revenue/Employee | 465,122.093 |
| Income Per Employee | -377,918.605 |
| Receivables Turnover | 17.814 |
| Total Asset Turnover | 0.215 |
VYGR Liquidity
| Current Ratio | 5.56 |
| Quick Ratio | 5.56 |
| Cash Ratio | 5.356 |
VYGR Profitability
| Gross Margin | 94.086 |
| Operating Margin | -104.107 |
| Pretax Margin | -80.42 |
| Net Margin | -81.251 |
| Return on Assets | -17.466 |
| Return on Equity | -24.251 |
| Return on Total Capital | -18.924 |
| Return on Invested Capital | -22.047 |
VYGR Capital Structure
| Total Debt to Total Equity | 14.587 |
| Total Debt to Total Capital | 12.73 |
| Total Debt to Total Assets | 11.125 |
| Long-Term Debt to Equity | 12.176 |
| Long-Term Debt to Total Capital | 10.626 |